Current perspectives on lipid lowering with statins to decrease risk of cardiovascular disease

Clinical Cardiology

Volumn 24, Issue 7 SUPPL. 2, 2001, Pages

  Hennekens, C H ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; High density lipoprotein cholesterol; Low density lipoprotein cholesterol; Statin; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; STATINE DERIVATIVE; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; EDUCATION PROGRAM; HUMAN; LIPID BLOOD LEVEL; META ANALYSIS; RISK BENEFIT ANALYSIS;

EID: 18244429930     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960240703     Document Type: Conference Paper

References (22)

1. Increasing burden of cardiovascular disease: Current knowledge and future directions for research on risk factors
2. Clinical and research challenges in risk factors for cardiovascular diseases
3. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
4. Report of the Expert Panel on population strategies for blood cholesterol reduction: Executive summary
5. State-of-the-art update and review: Clinical trials of lipid-lowering agents
6. Lowering blood cholesterol to prevent heart disease
7. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults
8. Lowering cholesterol concentrations and mortality: A quantitative review of primary prevention trials
9. Might treatment of hypercholesterolaemia increase non-cardiac mortality?
10. An overview of trials of cholesterol lowering and risk of stroke
11. Overview of results of randomized clinical trials in heart disease: II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification
12. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
13. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
14. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
15. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
16. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
17. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
18. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials
19. Cost-effectiveness of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era
20. Maximizing the cost-effectiveness of lipid-lowering therapy
21. The Lipid Treatment Assessment Project (L-TAP): A multicenter survery to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals